Showing results (2661-2670 of 2,680) with videos related to
Sort By:
Pageof 268
Breast Cancer Research : BCR|March 28, 2006
Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriersEitan Friedman, Joanne Kotsopoulos, Jan Lubinski, et al.Cell Reports|July 16, 2020
The Zscan4-Tet2 Transcription Nexus Regulates Metabolic Rewiring and Enhances Proteostasis to Promote ReprogrammingZhou-Li Cheng, Meng-Li Zhang, Huai-Peng Lin, et al.Neural Networks : the Official Journal of the International Neural Network Society|October 3, 2024
Federated learning via multi-attention guided UNet for thyroid nodule segmentation of ultrasound imagesZhuo Xiang, Xiaoyu Tian, Yiyao Liu, et al.Nature Cancer|June 15, 2023
Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLCCaicun Zhou, Ziping Wang, Meili Sun, et al.Genomics|February 5, 2021
Performance of common genetic variants in risk prediction for colorectal cancer in Chinese: A two-stage and multicenter studyCai-Yun He, Le-Zong Chen, Zi-Xian Wang, et al.Clinical Nutrition (Edinburgh, Scotland)|July 27, 2025
Prevalence and predictive importance for short-term clinical outcomes of GLIM-defined malnutrition among adult inpatients: A nationwide cross-sectional studyYan Liu, Yu Wang, Gaiyun Chen, et al.Science China. Life Sciences|January 22, 2025
Prevalence of malnutrition among adult inpatients in China: a nationwide cross-sectional studyYan Liu, Chunhua Song, Xue Wang, et al.Gut|May 17, 2023
Eradicating Helicobacter pylori via 13C-urea breath screening to prevent gastric cancer in indigenous communities: a population-based study and development of a family index-case methodWei-Yi Lei, Jian-Yu Lee, Shu-Ling Chuang, et al.BMJ Open|April 23, 2021
Integrating neuroimaging biomarkers into the multicentre, high-dose erythropoietin for asphyxia and encephalopathy (HEAL) trial: rationale, protocol and harmonisationJessica L Wisnowski, Stefan Bluml, Ashok Panigrahy, et al.The Lancet. Oncology|June 16, 2025
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trialCaicun Zhou, Ziping Wang, Meili Sun, et al.Pageof 268